Breaking Phoebe Bridgers Releases Third Studio Album ‘Lost Weekend’ Son of Former Mexican President López Obrador Denied U.S. Visa Michigan Regulators Propose Overhaul of Utility Profit Models Study Suggests ‘Normalizing’ Doctor Statements May Deter Patient Treatment Magnitude 7.4 Earthquake Devastates Colombia, Leaving Hundreds Dead and Thousands Homeless
Friday August 14, 2026
81° Providence, RI Mostly Clear
Become a Contributor
Section

Channels

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb’s First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Press Release

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb’s First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd)…

Business Wire · 8 minutes ago
Read Full Story